Generate Biomedicines Inc’s Quiet Period Will Expire on April 8th (NASDAQ:GENB)

Generate Biomedicines’ (NASDAQ:GENB) quiet period is set to end on Wednesday, April 8th. Generate Biomedicines had issued 25,000,000 shares in its IPO on February 27th. The total size of the offering was $400,000,000 based on an initial share price of $16.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are restricted from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, it’s expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.

Analyst Upgrades and Downgrades

GENB has been the subject of several research reports. Cantor Fitzgerald started coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They issued an “overweight” rating for the company. Piper Sandler initiated coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 target price on the stock. The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a research note on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target for the company. Zacks Research upgraded Generate Biomedicines to a “hold” rating in a report on Wednesday, March 25th. Finally, Morgan Stanley initiated coverage on Generate Biomedicines in a research note on Tuesday, March 24th. They issued an “overweight” rating and a $20.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $25.00.

Generate Biomedicines Stock Up 3.3%

NASDAQ:GENB opened at $13.75 on Friday. Generate Biomedicines has a 1-year low of $11.00 and a 1-year high of $15.32.

About Generate Biomedicines

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.